---
title: Xiangya Cardiopulmonary Health and Disease Cohort
nct_id: NCT06972784
overall_status: RECRUITING
sponsor: Xiangya Hospital of Central South University
study_type: OBSERVATIONAL
primary_condition: Respiratory Function Tests，Heart Function Tests
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06972784.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06972784"
ct_last_update_post_date: 2025-07-02
last_seen_at: "2026-05-12T06:41:34.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Xiangya Cardiopulmonary Health and Disease Cohort

**NCT ID:** [NCT06972784](https://clinicaltrials.gov/study/NCT06972784)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30000
- **Lead Sponsor:** Xiangya Hospital of Central South University
- **Conditions:** Respiratory Function Tests，Heart Function Tests, Cardiopulmonary Function
- **Start Date:** 2025-06-01
- **Completion Date:** 2035-12-01
- **CT.gov Last Update:** 2025-07-02

## Brief Summary

Xiangya Cardiopulmonary Health and Disease Cohort (XY-CPHDC) is a non-intervention study grounded in real-world data. It is designed as a bidrectional clinical cohort combined retrospective and prospective design, in order to evaluate cardiopulmonary function systematically and holistically, integrate physiology and medical theory, and explore the changing pattern of the cardiopulmonary under different health states. Cardiovascular System and Respiratory System are closely linked and interdependent physiological systems, and they play a vital role in maintaining normal life activities in the human body. Patients with cardiopulmonary disease often have conspicuous comorbidity characteristics, however, current measurements of cardiopulmonary function indicators are mostly limited to the assessments of single organ. This pattern of subspecialty care leads to deficiencies in the recognition of cardiopulmonary synergy dysfunction, and there is an urgent need for a more comprehensive and systematic approach to assessment. This study plans to construct a cardiopulmonary holistic assessment cohort, aiming at comprehensively and systematically reveal the intrinsic connection between the cardiopulmonary function in different scenarios, such as resting, exercise, and sleep, to deeply explore the core indicators of cardiopulmonary holistic function, to construct a joint stratification system of cardiopulmonary function, and to map cardiopulmonary comorbidity spectrum, so that they can accurately guide the diagnosis of the disease, the prognostic prediction and the intervention strategies.

## Detailed Description

1.2.1 Study objective

1. Construct a cardiopulmonary holistic assessment cohort covering the full range of resting-exercise-sleep scenarios and encompassing non-cardiopulmonary disease-- cardiopulmonary hypofunction--cardiopulmonary disease populations in the longitudinal development of time.
2. Explore the core indicators related to cardiopulmonary hypofunction and disease risk, and construct a joint stratification system of cardiopulmonary function.
3. Map the cardiopulmonary comorbidity spectrum and describe its functional characteristics using the cardiopulmonary holistic assessment cohort, and analyze the impact of comorbidity patterns on patient's long-term prognosis and clinical outcomes.

1.2.2 Study type Bidirectional cohort design Retrospective cohort: Integrate historical hospital data(e.g., electronic medical records, imaging reports, cardiopulmonary function test records) and select the study population according to the inclusion and exclusion criteria.

Prospect cohort: patients from the retrospective cohort were screened to meet the study requirements and agreed to participate in subsequent studies for long-term follow-up(≥3years) and dynamic monitoring of cardiopulmonary function changes, 1.2.3 study content Building a cardiopulmonary cohort: build a full range of clinical cohort covering resting, exercise, and sleep scenarios with non-diseased, hypofunctional and cardiopulmonary disease populations, integrating retrospective data analysis and prospective follow-up monitoring to comprehensively reflect the cardiopulmonary performance of individuals in different physiological states, and laying the data foundation for subsequent analyses.

Constructing a joint stratification system for cardiopulmonary function: based on the data collected from the cardiopulmonary holistic assessment cohort, further in-depth feature extraction of cardiopulmonary function indicators is performed, and key indicators capable of predicting cardiopulmonary function decline and disease risk are screened out through data mining and dynamic monitoring, integrating the core indicators into a multidimensional risk indicator system, and stratifying patients by using a clustering method or based on a risk score, dividing low, medium and high risk groups, and realize the dynamic update of the stratification model.

Characterizing the cardiopulmonary comorbidity spectrum: Using the constructed cardiopulmonary cohort and the stratification system, we will deeply reveal the functional characteristics of cardiopulmonary comorbidity, analyze the functional changes and characteristics of patients with cardiopulmonary comorbidity in different scenarios (e.g., resting, exercising, or sleeping), and depict the characteristics of cardiopulmonary comorbidity spectrum; through the cardiopulmonary co-morbidity spectrum, we will deeply explore the interaction mechanism between the heart and the lungs in the progression of the disease, and analyze the impact of comorbidity on the prognosis and clinical outcomes of patients.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
I1 Inclusion and exclusion criteria for retrospective cohorts 1) Inclusion criteria:

1. Patients were either treated or hospitalized in the physical examination center, outpatient and emergency clinic in the Xiangya Hospital of Central South University from January 2010 to April 2025.
2. Completion of cardiac function (e.g., echocardiography) and pulmonary function (e.g., pulmonary function test) assessment, with an interval of no more than 1 year between the two.
3. Those who had complete clinical diagnostic and therapeutic information (e.g., medical history, medication records, laboratory test results, imaging reports) except for the cardiopulmonary function test report.

2)Exclusion criteria

1. Patients with complete loss of cardiopulmonary function test reports or key data (e.g., VO2peak, FEV1/FVC, LVEF).
2. Patients with loss of key clinical diagnostic and treatment data (e.g., medical history, medication records, laboratory test results).

2.1.2 Inclusion and exclusion criteria for prospective cohort

1）Inclusion criteria

1. Patients who have been included in the retrospective cohort.
2. Voluntarily signed informed consent form to participate in long-term follow-up for ≥3 years.
3. Able to complete the baseline assessment of the prospective cohort (including cardiopulmonary function retesting, questionnaires, etc.).
4. Stable conditions for follow-up (e.g., living in the local area, available valid contact information, no plans to move in the short term or go out for a long period of time).

2\) Exclusion Criteria.

1. Patients who have been excluded from the retrospective cohort or for whom key data are missing.
2. With severe cognitive impairment, psychiatric disease or verbal communication disorder, unable to cooperate with follow-up and data collection.
3. Expected survival time \<3 years (e.g., advanced malignancy, end-stage cardiopulmonary failure, etc.).
4. Incomplete cardiopulmonary function or other clinical data during the baseline assessment.
5. Those who plan to participate in other interventional clinical trials that may interfere with the assessment of cardiopulmonary function.
```

## Arms

- **Retrospective cohort**
- **Prospective cohort**

## Primary Outcomes

- **Death event** _(time frame: From participants agreed to participate in this study until the date of death from any or specific cause or the end of the study, whichever came first, assessed up to 10 years)_ — Death due to any cause or specific cause

## Secondary Outcomes

- **Life quality as measured by the 12-item short form health survey (SF-12).** _(time frame: Through study completion, an average of 3 years)_
- **Hospitalization Costs** _(time frame: Through study completion, an average of 3 years)_
- **Number of participants with cardiometabolic diseases or events** _(time frame: Through study completion, an average of 3 years)_
- **Number of participants with respiratory diseases or events** _(time frame: Through study completion, an average of 3 years)_

## Locations (1)

- Xiangya Hospital, Central South University Affiliated, Changsha, Hunan, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.xiangya hospital, central south university affiliated|changsha|hunan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06972784.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06972784*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*